NasdaqGM:SUPNPharmaceuticals
Supernus Pharmaceuticals (SUPN) Is Up 7.6% After Record Sales But 2025 Net Loss And Cautious 2026 Outlook
In February 2026, Supernus Pharmaceuticals reported fourth-quarter 2025 revenue of US$211.57 million and record full-year 2025 revenue of US$718.95 million, but swung to a full-year net loss of US$38.55 million and guided 2026 operating earnings to a range of US$0–US$30 million on expected total revenues of US$840–US$870 million.
The results highlighted strong contributions from newer CNS products such as Qelbree, GOCOVRI, ZURZUVAE, and newly approved ONAPGO, alongside the completed Sage...